Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A.

Berger M, Raslan Z, Aburima A, Magwenzi S, Wraith KS, SPurgeon BEJ, Hindle MS, Law R, Febbraio M, Naseem KM.

Haematologica. 2019 Jul 9. pii: haematol.2018.213348. doi: 10.3324/haematol.2018.213348. [Epub ahead of print]

2.

TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice.

Smith CW, Raslan Z, Parfitt L, Khan AO, Patel P, Senis YA, Mazharian A.

Blood Adv. 2018 Aug 28;2(16):2072-2078. doi: 10.1182/bloodadvances.2018017756. No abstract available.

3.

Dyslipidemia-associated atherogenic oxidized lipids induce platelet hyperactivity through phospholipase Cγ2-dependent reactive oxygen species generation.

Berger M, Wraith K, Woodward C, Aburima A, Raslan Z, Hindle MS, Moellmann J, Febbraio M, Naseem KM.

Platelets. 2019;30(4):467-472. doi: 10.1080/09537104.2018.1466386. Epub 2018 May 7.

4.

Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability.

Yusuf MZ, Raslan Z, Atkinson L, Aburima A, Thomas SG, Naseem KM, Calaminus SDJ.

Sci Rep. 2017 Jul 17;7(1):5582. doi: 10.1038/s41598-017-05817-9.

5.

Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive Platelets.

Smith CW, Thomas SG, Raslan Z, Patel P, Byrne M, Lordkipanidzé M, Bem D, Meyaard L, Senis YA, Watson SP, Mazharian A.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):823-835. doi: 10.1161/ATVBAHA.117.309253. Epub 2017 Mar 23.

PMID:
28336561
6.

The Spatiotemporal Regulation of cAMP Signaling in Blood Platelets-Old Friends and New Players.

Raslan Z, Aburima A, Naseem KM.

Front Pharmacol. 2015 Nov 10;6:266. doi: 10.3389/fphar.2015.00266. eCollection 2015.

7.

Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition by the 3',5'-cyclic adenosine monophosphate-signaling pathway.

Raslan Z, Magwenzi S, Aburima A, Taskén K, Naseem KM.

J Thromb Haemost. 2015 Sep;13(9):1721-34. doi: 10.1111/jth.13042. Epub 2015 Aug 12.

8.

Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.

Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, McNeil C, Wheatcroft S, Yuldasheva N, Febbriao M, Kearney M, Naseem KM.

Blood. 2015 Apr 23;125(17):2693-703. doi: 10.1182/blood-2014-05-574491. Epub 2015 Feb 20.

9.

Compartmentalisation of cAMP-dependent signalling in blood platelets: The role of lipid rafts and actin polymerisation.

Raslan Z, Naseem KM.

Platelets. 2015;26(4):349-57. doi: 10.3109/09537104.2014.916792. Epub 2014 May 15.

PMID:
24832788
10.

The control of blood platelets by cAMP signalling.

Raslan Z, Naseem KM.

Biochem Soc Trans. 2014 Apr;42(2):289-94. doi: 10.1042/BST20130278. Review.

PMID:
24646233
11.

cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway.

Aburima A, Wraith KS, Raslan Z, Law R, Magwenzi S, Naseem KM.

Blood. 2013 Nov 14;122(20):3533-45. doi: 10.1182/blood-2013-03-487850. Epub 2013 Oct 7.

Supplemental Content

Loading ...
Support Center